Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Eastern District of Texas on behalf of shareholders of Orthofix Medical, Inc. who purchased shares between October 11, 2022 and September 12, 2023.
Orthofix and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 12, 2023, the Company announced the appointment of an interim CEO, interim CFO, and interim CLO, effective immediately, following the “unanimous decision by the Board’s independent directors to terminate for cause [President and CEO] Keith Valentine, [CFO] John Bostjancic and [CLO] Patrick Keran from those respective roles” due to an independent investigation that revealed that “each of these executives engaged in repeated inappropriate and offensive conduct that violated multiple code of conduct requirements and was inconsistent with the Company’s values and culture.”
On this news, the price of Orthofix’s shares fell $5.62 per share, or over 30%, to close at $13.01 per share on September 13, 2023, on unusually heavy volume.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until October 21, 2024 to request that the court appoint them lead plaintiff.